Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Jefferies Sticks to Their Hold Rating for Genmab A/S (0MGB)
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Truist Financial Maintains Genmab(GMAB.US) With Buy Rating
Barclays Reaffirms Their Buy Rating on Genmab A/S (0MGB)
Genmab (GMAB) Gets a Buy From Truist Financial
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Genmab Analyst Ratings